NeuroDerm Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Subsidiary
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.neuroderm.com
Clinical Trials
16
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
- Conditions
- Parkinson's Disease
- Interventions
- Combination Product: Placebo for SC infusionDrug: Oral IR-LD/CDCombination Product: ND0612 Solution for SC infusionDrug: Placebo for Oral IR-LD/CD
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 381
- Registration Number
- NCT04006210
- Locations
- 🇺🇸
Xenoscience, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Cedar- Sinai Medical Center Department of Neurology, Los Angeles, California, United States
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
- Conditions
- Parkinson
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- NeuroDerm Ltd.
- Registration Number
- NCT03462043
- Locations
- 🇮🇹
91601, Roma, Italy
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- NeuroDerm Ltd.
- Registration Number
- NCT02782481
- Locations
- 🇮🇱
Haddasah Ein Kerem Medical center, Jerusalem, Israel
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT02726386
- Locations
- 🇺🇸
Xenoscience, Phoenix, Arizona, United States
🇺🇸Clinical Trials Inc., Little Rock, Arkansas, United States
🇺🇸The Parkinsons and Movement Disorder Institute, Fountain Valley, California, United States
A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02604914
- Locations
- 🇬🇧
Quotient Clinical LTD, Ruddington, Nottingham, United Kingdom
- Prev
- 1
- 2
- 3
- Next